The matricellular protein Cysteine rich 61 (Cyr61) displays a remarkable diversity of multiple cellular functions involved in significant physiologic and pathologic processes. Cyr61 is known as an important player in tumor progression, promoting neovascularization and metastasis. Our prior investigations elucidated an oxygen-dependent Cyr61 alternative splicing process characterized by retention of its intron 3, regulating its biological function in a hypoxia-driven on/off switch mechanism. In this work, we identified extracellular acidosis as a potent inducer for altered Cyr61 alternative splicing pattern regulating Cyr61 expression. Intriguingly, splicing factor hTRA2-beta1 displayed an opposite effect on Cyr61 expression. Nuclear hTRA2-beta1 protein expression was found markedly reduced under acidic conditions. In keeping with these conclusions, we show that hTRA2-beta1 can specifically bind a 'GAAG' motif in Cyr61 exon 3 RNA, that the splicing factor displays acidosis-dependent protein localization in cellular compartments, and shRNA-mediated hTRA2-beta1 knock-down triggers the same effects on Cyr61 alternative splicing like acidosis or hypoxia. Our findings strongly support the hypothesis of a specific regulation of Cyr61 expression by hTRA2-beta1.
INTRODUCTION
Over the past decade, a growing number of studies have demonstrated the correlation between aberrant splicing processes and various human diseases. Aside from human genetic disorders, defective pre-mRNA splicing has also been linked to different kinds of cancer (1, 2) .
Cyr61 (Cysteine rich 61), a prototype member of the CCN protein family (3) , is a secreted growth-factor inducible, immediate-early gene (4) . The pro-angiogenic Cyr61 protein displays a remarkable diversity of multiple cellular activities and biological functions (5, 6) . On this account, Cyr61 plays important roles in physiological and pathological processes (7) and could also be linked to tumor progression (8 -10) . Multiple factors induce Cyr61 transcription, e.g. growth factors (11, 12) , chemokines, estrogen, tumor necrosis factor-a (13) and hypoxia (8, 14) . Interaction of Cyr61 with different integrins through an autocrine -paracrine mechanism (6) activates several signaling pathways, e.g. Wnt (15) , NF-kB (16) , tyrosine kinase and Akt (6) . In tumor progression, Cyr61 overexpression may cause an up-regulation of its own receptors in an autocrine signaling loop (8, 16) .
Our prior investigations identified for the first time a hypoxia-induced alternative splicing process for the human Cyr61 gene. Apart from the constitutively expressed, proteingenerating transcript, we were able to detect an alternative intron 3 retaining mRNA variant that is incapable to generate biologically active Cyr61 protein. Expression of the proteingenerating transcript significantly correlated with advanced stages in breast cancer. Hypoxia was identified as a specific modulator of Cyr61 alternative splicing triggering a significant shift toward Cyr61 protein synthesis with potential biological consequences in tumor cells (14) .
From the literature, it is known that hypoxia and its concomitants, e.g. cellular acidosis, are tumorbiological important inducers for transcriptional cascades promoting aggressive cancer phenotypes (17) (18) (19) . Acidosis was shown to regulate VEGF-A (vascular endothelial growth factor-A) alternative splicing, * To whom correspondence should be addressed. Tel: +49 76127030880; Fax: +49 76127031690; Email: marc.hirschfeld@uniklinik-freiburg.de # The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com most likely through the involvement of SR proteins. In this context, changes in the splicing pattern may represent an adaption of tumor cells to the altered peritumoral environment via the activation of angiogenic signaling pathways leading to different isoform production (20) . Noteworthy, a 5 ′ cap-independent translation mechanism enables Cyr61 mRNA processing into functional protein even under cellular stress situations (21, 22) .
The importance of alternative mRNA splicing on proteome diversity is augmented by its pertinent role in the regulation of gene expression (23) . Gene functions can be down-regulated by expression of non-functional alternative mRNA variants, resulting in regulated unproductive splicing and translation (RUST) (23, 24) . Cyr61 alternative splicing introduces premature stop codons, most likely leading to post-transcriptional mRNA degradation via nonsense-mediated decay (NMD) (14) . From a trans-acting factor point of view, the SR-like and sequence-specific splicing enhancer human TRA2-beta1 protein has been described to bind efficiently to the degenerate sequence GHVVGANR (25, 26) , which is also present within the Cyr61 sequence. Recent investigations point out that the sequence motif 'RAAG' can be sufficient for binding of the splicing factor (S. Stamm, Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, KY, USA, unpublished data). Human TRA2-beta1 autoregulates its own expression via inclusion of a stop codon-containing exon in its mRNA (25) . Intracellular localization of this splicing factor was shown to be influenced by altered cellular conditions and could also be associated with changes in alternative splicing (27, 28) .
Our present study has now identified extracellular acidosis and splicing factor hTRA2-beta1 as specific regulators of alternative Cyr61 mRNA splicing. The frequently observed hypoxic and acidic conditions in proliferating tumor tissues abrogate the inhibitory effect of hTRA2-beta1 on Cyr61 protein expression by triggering subcellular translocation of the splicing factor from nucleus to cytoplasm.
We therefore postulate that the interplay between tumorbiological epiphenomena and hTRA2-beta1 specifically regulates Cyr61 alternative splicing. The translational activation of the pro-angiogenic Cyr61 protein is a potentially pertinent incident for the promotion of tumor progression.
RESULTS

Analogous effects of hypoxia and acidosis on Cyr61 alternative splicing
In a previous work, we have identified hypoxia as a key regulator in Cyr61 alternative splicing (14) . To clarify whether the oxygen deficiency itself or its concomitant effect, cellular acidosis, was influencing the alternative splicing pattern of Cyr61, functional cell culture experiments were now performed. As shown in Figure 1 , cancers cells cultivated under acidic conditions exhibited a significant shift in Cyr61 alternative splicing toward the Cyr61 intron 3-free isoform. Most importantly, all tested cancer cell lines displayed this observed concordance of an analogous regulatory influence of hypoxia and acidosis on Cyr61 splice variant expression (Fig. 1A) . Next, Cyr61 protein expression was determined by western blot analyses in cancer cells cultured under regular culture conditions compared with hypoxic or acidic treatment ( Fig. 1B and C) . The results show the same effect on protein expression (i.e. generation of a biological active Cyr61 protein) of both acidosis and hypoxia. Taken together, therefore, we concluded that acidosis triggered an analogous effect on Cyr61 expression such as hypoxic conditions.
The intracellular localization of the Cyr61 protein was then investigated by immunocytochemical analyses of cancer cells treated under acidic versus normal conditions. In analogy to hypoxia (14) , acidosis led to markedly increased nuclear and cytoplasmic expression of Cyr61, in contrast to the extremely low expression levels found in cells cultivated under regular conditions (Fig. 2, series 1) . Quantitative detection of the Cyr61 protein in regularly cultivated cancer cells by western blot was only marginal, and can be assessed as 'negative' in comparison to the protein levels detectable under hypoxia or acidosis. Immunocytochemistry revealed very low levels of Cyr61 protein located in the cellular membrane of cells under regular conditions. Elevated protein levels in regularly treated cells were observed exclusively in cytoplasmic and nuclear cellular compartments of individual cells currently undergoing stages of nuclear division within mitosis process. With regards to the exact level of acidosis induced in the cancer cell lines, the pH values of the conditioned culture media were analysed in all investigated cell lines after 24 h of treatment. The mean value of the extracellular pH was 7.4 under regular, 6.85 under hypoxic conditions and 6.65 under acidic culture conditions. To investigate whether these changes in Cyr61 alternative splicing pattern originate from deprivation of oxygen itself or simply from the altered pH under hypoxic conditions, cobalt-(II)chloride was used to induce chemical hypoxia. Cobalt is known to mimic hypoxia in part via the occupation of the VHL (von Hippel-Lindau)-binding domain of HIF1-a, thereby preventing HIF1-a protein degradation and promoting the HIFdependent regulation of gene expression (29) . According to the triplicate cobalt induction experiments, however, we were able to demonstrate that Cyr61 mRNA alternative splicing pattern was not affected by chemically induced hypoxia. Thus, we were able to exclude the involvement of a HIF-1a-mediated pathway in the regulation of Cyr61 alternative splicing (Fig. 3 ).
hTRA2-beta1 regulates Cyr61 alternative splicing
Human breast, cervical and ovarian cancer is characterized by elevated levels of hTRA2-beta1 expression. The impact of this overexpression is potentially very important since this splicing factor displays regulatory influence on alternative splicing decisions of several tumor-relevant genes (30) (31) (32) .
Therefore, to investigate whether hTRA2-beta1 could be involved in Cyr61 alternative splicing, functional experiments manipulating hTRA2-beta1 expression levels in cancer cells were performed. Alterations in the expression levels of Cyr61 splice variants were examined in cells cultivated under normal conditions in comparison to cells transiently transfected with hTRA2-beta1 expression plasmid, hTRA2-beta1 shRNA plasmid and control shRNA plasmid A. Forced hTRA2-beta1 overexpression resulted in an analogous Cyr61 alternative splicing pattern as observed with hTRA2-beta1 expression levels under normal culture conditions, whereas the Cyr61 intron 3 retaining mRNA isoform was predominately expressed and the intron 3 skipping variant was hardly detectable. Cells treated with control shRNA plasmid A displayed no difference in Cyr61 alternative splicing pattern compared with normal culture conditions (data not shown). In contrast, the downregulation of hTRA2-beta1 mediated by hTRA2-beta1 shRNA lead to a remarkable shift in Cyr61 alternative splicing pattern toward the Cyr61 intron 3-free mRNA isoform (Fig. 4) . Therefore, both Cyr61 mRNA isoforms could be detected in hTRA2-beta1 knock-down cells. From these results, we hypothesize that hTRA2-beta1 is a specific regulator of Cyr61 alternative splicing, by promoting the expression of the Cyr61 intron 3 retaining mRNA isoform and thereby inhibiting the generation of biological active Cyr61 protein.
hTRA2-beta1 protein localization is influenced by acidosis
The intracellular expression and localization of hTRA2-beta1 protein was determined immunocytochemically in cells cultured under normal, hypoxic and acidic conditions.
In all investigated cell lines, hTRA2-beta1 protein expression displayed a distinct nuclear localization under normal conditions. In contrast, under hypoxic conditions, this protein displayed a significant switch to an increased presence in the cytoplasm accompanied by a markedly reduced nuclear expression. Even more concisely, the shift in hTRA2-beta1 protein localization toward a reduced nuclear expression and accompanied by an increase in cytoplasmatic expression was also observed in cells cultivated under acidic conditions (Fig. 5 ). These immunocytochemical findings support strongly 
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Human Molecular Genetics, 2011, Vol. 20, No. 12 the hypothesis that hTRA2-beta1 is involved in Cyr61 alternative splicing regulation. In fact, while normoxia was accompanied by a strong nuclear hTRA2-beta1 expression in cancer cells, the Cyr61 protein was hardly detectable under sufficient oxygen availability. On the other hand, deprivation of nuclear hTRA2-beta1 expression and its translocation to the cytoplasm caused by hypoxia/acidosis could have abrogated the inhibitory influence of hTRA2-beta1 on Cyr61 protein expression by triggering a shift in its alternative splicing pattern. In this respect, therefore, absence of the hTRA2-beta1 protein would have resulted in predominant expression of Cyr61 intron 3-free mRNA variant, the only mRNA variant that is capable of generating a biologically active protein.
hTRA2-beta1-binding interaction to GAAG motif in Cyr61 exon 3
Finally, we wanted to establish a direct link between Cyr61 alternative splicing of intron 3 and hTRA2-beta1. An overview of the genomic sequence of the human Cyr61 gene surrounding exon 3 -intron 3 -exon 4 was observed to contain multiple potential binding motifs for this splicing factor (GHVVGANR) (25, 26) and even more frequently the motif 'RAAG' (S. Stamm, Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, USA, unpublished data). In addition to these considerations, a recent report by Tsuda et al. (33) found that the AGAA tetranucleotide was specifically recognized by this protein.
Because the exon 3, intron 3 and exon 4 regions are particularly rich in these kind of motifs, we tested four 60 nt sequence fragments spanning Cyr61 exon 3 -intron 3 -exon 4 range in pull-down analyses to investigate their potential binding interaction with the hTRA2-beta1 protein.
In detail, fragments covered sequence ranges as follows: fragment 1, exon 3 -intron 3; fragment 2, intron 3; fragment 3, intron 3-exon 4; fragment 4, exon 4 (Fig. 6A) . As a positive control, we used in the analysis a SMN (survival of motoneuron) exon 7 sequence fragment that was already known to contain an established hTRA2-beta1-binding motif (34) . As shown in Figure 6B , fragment 1 was the only one that displayed significant binding activity to this splicing factor (Fig. 6B) . In order to better map this interaction, we then decided to mutate the most suspect 'RAAG' sequences within this region. Therefore, we performed additional pulldown analyses using fragment 1 wild-type and three combinatorially mutated fragments: mutation 1, loss of AAAG motif; mutation 2, loss of GAAG motif; mutation 3, loss of both RAAG motifs (Fig. 6C) . The analyses clearly identified the GAAG motif in Cyr61 exon 3 (position nt 1511-1514) as a target for hTRA2-beta1-binding activity (Fig. 6D) . Taken together, these results suggest that the direct binding of hTRA2-beta1 to the GAAG motif in Cyr61 exon 3 pre-mRNA promotes the retention of intron 3 in the Cyr61 mRNA and thereby inhibits the generation of biologically active protein.
DISCUSSION
The increasing importance of alternative splicing as a pivotal mechanism in regulation of gene expression has become more and more evident over the past years. It is now clear, in fact, 
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that the splicing machinery heavily contributes to biological complexity and especially to the ability of cells to adapt in different developmental stages and altered cellular conditions (23, 24) . As a result, a large number of proteins are under the regulatory influence of alternative splicing, which determines their binding properties, intracellular localization, enzymatic activity, protein stability and posttranslational modifications (24) . The generation of non-functional isoforms of an active gene product causing the down-regulation of the function of a gene is one common outcome of alternative splicing (23) . Previously, we have demonstrated the existence of two different mRNA isoforms of the human Cyr61 gene. In addition to the constitutively spliced mRNA variant, we identified an alternatively spliced mRNA variant characterized by the retention of full-length intron 3 (14) . The intron 3 retaining Cyr61 mRNA variant is not capable to generate biologically active Cyr61 protein, and is most likely subjected to degradation by NMD. Intron 3 retention leads to the insertion of two stop codons within the intronic sequence and via frameshift to additional stop codons in exons 4 and 5 with the high possibility for NMD, as described for introduced stop codons which are more than 50-55 nt upstream of the 3 ′ -most exon-exon junction (24) . RUST (23) is most likely the process governing the intron 3 retaining Cyr61 mRNA isoform. Our previous studies revealed that breast cancer carcinogenesis was accompanied by a stepwise, stage dependent shift from the intron 3 retaining towards the intron 3 skipping mRNA phenotype, leading to the processing of a biologically active Cyr61 protein.
Additionally, we could demonstrate that hypoxia serves in an autoregulatory loop via induction of alternative splicing as a central regulator for Cyr61 protein activation. Thus, hypoxia triggered Cyr61 protein expression, supporting its function as a pro-angiogenic factor and promoter of tumor progression (14) .
To elucidate the molecular background of this observed Cyr61 alternative splicing mechanism, we have now investigated the potential influence of splicing regulators, especially with regards to our prior functional conclusions. Splicing factor hTRA2-beta1 is a very potent activator of pre-mRNA splicing (30, 35) and, very interestingly from our point of view, cellular hTRA2-beta1 protein localization was reported to be influenced by altered oxygen conditions caused by ischemia, accompanied by a change of alternative splicing pattern in brain cells (28) .
In this work, we have been able to demonstrate that hTRA2-beta1 expression has a distinct influence on Cyr61 alternative splicing pattern. The down-regulation of hTRA2-beta1 expression mediated by transiently transfected hTRA2-beta1 shRNA led to a significant shift toward the expression of the constitutively spliced intron 3-free Cyr61 mRNA isoform, whereas the expression of the alternatively spliced intron 3 retaining Cyr61 variant was markedly reduced (Fig. 4) .
Microenvironment is an important biological issue for cancer cells. Solid tumors frequently show an up-regulation of glycolysis and growth under hypoxic conditions. Under these circumstances, tumor cells generate large amounts of metabolic acid by glucose utilization, lactic acid production and increased proton efflux, thus preventing apoptosis by cellular acidosis (18) . The intracellular pH in normal tissues is generally similar compared with the pH in solid tumors. In contrast, the extracellular pH is higher in normal tissue and lower in solid tumors, causing a significant difference in the cellular pH gradient of the different types of tissues (36) . We therefore presumed that Cyr61 alternative splicing is not only influenced by hypoxia, but also by its concomitant effect: acidosis. Cellular acidosis showed an analogous effect on the Cyr61 splice mechanism on both, RNA and protein level. Lower extracellular pH promotes the expression of constitutively spliced Cyr61 mRNA, which results in the generation of biologically active Cyr61 protein. In contrast to the RNA processing of the vast majority of other genes, Cyr61 RNA translation is also effectively performed under patho-physiological stress situations, enabled by a cap-independent, internal ribosome entry site-mediated translation mechanism (22) . Therefore, Cyr61 protein expression is not limited by microenvironmental alterations such as hypoxia or extracellular acidosis.
According to the results obtained by chemical hypoxia experiments using cobalt(II)chloride, we further established that the Cyr61 alternative splicing mechanism is not directly influenced by HIF-1a-mediated signaling pathways or HIF-1a-regulated transcription. Exclusion of HIF-dependent regulation supported, therefore, the hypothesis that Cyr61 alternative splicing is not regulated by hypoxia itself, but by the accompanying metabolic alterations resulting in extracellular acidosis.
Taking the findings of Daoud et al. (28) into account, we then investigated hTRA2-beta1 protein localization under normal, as well as under hypoxic and acidic conditions. Our results have shown that there is a significant shift in the intracellular localization of the splicing factor from distinct nuclear expression under normal conditions to a markedly reduced nuclear expression, accompanied by a pronounced cytoplasmic expression under hypoxia or acidosis, respectively. The cytoplasmatic hTRA2-beta1 protein is most likely in a hyperphosphorylated state, according to previous conclusions (28) .
Proliferating tumors are characterized by oxygen deficiency and acidic extracellular conditions (17, 36, 37) . Downregulation of nuclear hTRA2-beta1 could therefore be part of a cascade of cellular adaptations supporting the expression of the pro-angiogenic Cyr61 protein, thereby promoting the progression of an aggressive phenotype (8, 38, 39) .
Finally, we were able to demonstrate that splicing factor hTRA2-beta1 binds specifically to GAAG motif in Cyr61 exon 3 RNA, thereby creating the substructure for the Cyr61 alternative splicing mechanism. This sequence is very similar to a preferred hTRA2-beta1-binding motif (AGAA) recently characterized by Tsuda et al. (33) . In this respect, it is interesting to note that several AGAA motifs are also present in fragments 2, 3 and 4, which nonetheless do not seem to appear as hTRA2-beta1-binding sites according to our pull-down analysis. There are several reasons that may account for this, RNA secondary structure predictions suggest that some of them might be blocked in a double-stranded configuration (although this is true also for our experimentally determined GAAG motif, data not shown). Alternatively, additional trans-acting factors binding to fragment 1 might promote recognition of this sequence by hTRA2-beta1 or the AGAA sites might be occupied by other interactions. In this respect, preliminary evidence has shown that fragment 4 can specifically bind the SF2/ ASF (splicing factor 2/alternative splicing factor) that also likes to recognize polypurinic sequences such as GAA (E.B., unpublished data). Further work is currently under way to better define all these interactions.
Nonetheless, at present we can hypothesize that binding of the trans-acting factor to the GAAG motif of Cyr61 exon 3, which is positioned very close to the exon 3 -intron 3 junction, abrogates constitutive splicing of intron 3. Considering the fact that intron 3 is relatively short (131 nt) and its retention is commonly detectable under regular cellular conditions, it can probably be characterized as an 'alternative intron' that undergoes 'exonization'. A similar phenomenon was described for a 116 nt long alternative intronic sequence of the last exon of the TPO (thrombopoietin) gene (1, 40) .
Considering our functional data on Cyr61 splicing, we postulate that hTRA2-beta1 acts as a specific silencer in the alternative mRNA processing of human Cyr61. In the TRA2 fruitfly (Drosophila melanogaster) homologue, Qi et al. (41) identified an intronic silencer element responsible for the inclusion of its own M1 intron, suggesting that this splicing factor can cause either splicing activation or repression. Intron 3 retention would therefore be due to the binding of hTRA2-beta1 protein to exon 3, resulting in the generation of the alternatively spliced Cyr61 isoform, which is not capable to generate biologically active Cyr61 protein.
Depletion of the hTRA2-beta1 protein caused by forced downregulation or via the hypoxia-or acidosis-mediated dislocation from the nucleus abrogates this splicing effect and leads to generation of constitutively spliced Cyr61 mRNA, succeeded by Cyr61 protein expression.
Tumor cell progression is affected by its accompanying serial changes in oxygenation state and subsequent metabolic modulation, creating a shift in cellular signaling pathways. Hypoxia and acidosis provoke the elimination of nuclear hTRA2-beta1, thus triggering Cyr61 pre-mRNA splicing toward expression of the protein-generating mRNA isoform, hence contributing to pro-angiogenic, tumor-promoting Cyr61 activity (Fig. 7) . Figure 7 . Regulation of Cyr61 alternative splicing by hTRA2-beta1. The interplay of cellular conditions and the acidosis-dependent intracellular localization of splicing factor hTRA2-beta1 govern Cyr61 alternative mRNA splicing regulation. (A) Under regular physiologic conditions: nuclear splicing factor hTRA2-beta1 with normal phosphorylation status binds to Cyr61 pre-mRNA in GAAG motif of exon 3 and efficiently promotes the retention of intron 3. The Cyr61 intron 3 retaining mRNA is subject to mRNA degradation (NMD). (B) Concomitant epiphenomena of oxygen deprivation (hypoxia /acidosis) triggers translocation of the hTRA2-beta1 protein from nucleus to cytoplasm, accompanied by a hyperphosphorylation (P) that inactivates its RNA binding activity. Absence of hTRA2-beta1 alternative splicing regulation leads to expression of constitutively spliced Cyr61 intron 3-free mRNA isoform and subsequently to translation in biologically active Cyr61 protein, enabling its tumor-promoting effects.
In conclusion, the interplay of splicing factor hTRA2-beta1 and tumorbiological concomitants represents a further step in the elucidation of Cyr61 alternative splicing mechanism and its biological consequences. This gain in knowledge will open up new vistas for prospective selected treatment in antiproliferative tumor therapy. 
MATERIALS AND METHODS
Plasmids
Cell culture and transient transfections
Cultured in a humidified incubator (378C in 5% CO 2 , 95% air), the established human tumor cell lines HeLa, Ishikawa and SK-OV-3 were maintained in Dulbecco's modified Eagle medium (DMEM), MCF-7 in Iscove's modified Dulbecco's medium (Life Technologies, Invitrogen), supplemented with 10% newborn bovine serum (PAA Laboratories GmbH), 1% of 1 mol/L HEPES buffer (Life Technologies) and 100 U/mL penicillin/streptomycin (PAA Laboratories GmbH). For acidosis experiments, culture media were supplemented with lactic acid (0.2%, pH 6.2). Cells were cultured in parallel experiments under normal conditions (used as control), and for 24 h under acidic conditions. For hypoxia experiments, cultures were transferred to hypoxic culture conditions (1% O 2 ; mentioned as hypoxia) in a hypoxic chamber placed in the same incubator. Cells were cultured in parallel experiments under normal oxygen conditions (95% air, mentioned as normoxia, used as control), and for 24 h under hypoxic conditions. Extracellular pH values were determined following 24 h treatment by analysis of culture media using Inolab pHmeter Level 1 (WTW, Germany).
To induce 'chemical hypoxia', cells were plated and grown under regular culture conditions for 24 h before culture media were changed to additive-free DMEM (Life Technologies, Invitrogen), supplemented with 150 mM CoCl 2 (Sigma-Aldrich Co.). For the immunocytochemical detection of Cyr61 and hTRA2-beta1 protein, cell lines HeLa, Ishikawa, SK-OV-3 and MCF-7 were cultured on four-chamber culture slides (BD Falcon, BD Biosciences, Europe), each under normal conditions and undergoing transient transfection as previously described with hTRA2-beta1 shRNA plasmid, control shRNA plasmid A and hTRA2-beta1 expression plasmid. Experiments concluded with the immediate fixation of treated cultures for immunocytochemistry.
RNA extraction and RT -PCR analyses
Total RNA from treated cells was isolated using TRIzol w Reagent (Invitrogen TM ) following the manufacturer's protocol, whereas the same sample was used for protein isolation in parallel. In total, 1 mg of purified RNA, as determined by optical densitometry, was transcribed to cDNA using Moloney murine leukemia virus reverse transciptase (Promega), RiboLock TM RNAse inhibitor (Fermentas Life Sciences) and anchored oligo dT Primer (T (9) VN (2) ) (Apara Bioscience). Prior to PCR, contamination with genomic DNA was prevented by digestion (1 h, 378C) with dpnI enzyme (Fermentas Life Sciences). The cDNA served as template for PCR (35 cycles) using Taq polymerase (Genaxxon Bioscience) and primers specific for exons 3 -4 of Cyr61 (5 ′ -primer:
. Expected amplicon sizes were 481 bp for Cyr61 intron 3-free mRNA variant, 612 bp for Cyr61 intron 3 retaining mRNA variant, 418 bp for hTRA2-beta1 and 305 bp for 18S RNA. All results from RT -PCR for Cyr61 and hTRA2-beta1 products were normalized using the corresponding 18S RNA expression as a comparative value.
Protein extraction and western blot
Protein extraction from cells was performed following the manufacturer's protocol of TRIzol w Reagent (Invitrogen TM ). Protein concentrations were determined by the bicinchoninic acid assay method.
Western Blot technique was performed according to the recommendations of Schagger and von Jagow (43) . Immunodetection was carried out by the use of a monoclonal mouse IgG antibody raised against the Cyr61 protein (#MAB4055, R&D Systems, Wiesbaden, Germany) and a peroxydaseconjugated secondary anti-mouse antibody (Sigma-Aldrich, Seelze, Germany). Loading control was executed using a rabbit IgG antibody aimed to cytochrome c oxidase IV (#3E11, Cell Signaling, Frankfurt, Germany) and a peroxydase-conjugated secondary anti-rabbit antibody (Dianova, Hamburg, Germany). Enhanced chemiluminescence detection of proteins was carried out with SuperSignal West Pico Subtrate (Perbio, Bonn, Germany).
Pull-down analysis
The RNA probes containing various portions of the Cyr61 exon 3-intron-exon 4 sequence (see below) were transcribed according to the established protocols (44), using as template sets of annealed oligos. Sense and antisense oligos carried a T7 polymerase promoter sequence and a four-consensus-binding motif for TDP-43. For in vitro pull-down assays, 500 pmol of the target RNAs were placed in a 400 ml reaction mixture containing Human Molecular Genetics, 2011, Vol. 20, No. 12 2363 (Sigma-Aldrich); incubated for 1 h in the dark at RT; ethanol precipitated; and resuspended in 100 ml of 0.1 M NaOAC, pH 5.0. Three hundred microliters of adipic acid dihydrazide agarose bead 50% slurry (Sigma-Aldrich) were added, and the mixture was equilibrated in 100 mM NaOAC, pH 5.0 and then incubated for 12 h at 48C on a rotator. The RNA beads were then pelleted, washed three times with 1 ml of 2 M NaCl and equilibrated in washing buffer (5 mM Hepes, pH 7.9, 1 mM MgCl 2 and 0.8 mM magnesium acetate). They were then incubated on a rotator with a protein mixture containing 1 mg of HeLa cell nuclear extract for 30 min at RT in 1 ml final volume. The beads were then pelleted by centrifugation at 3 000 rpm for 3 min and washed four times with 1.5 ml of washing buffer before the addition of SDS sample buffer and loading on a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gel. The materials were analyzed by western blotting with anti-hTRA2-beta1 (courtesy of S. Stamm) and with a rabbit polyclonal antibody directed against TDP-43 (made in the F.E. Baralle laboratory according to standard immunization procedures). The following sequences were transcribed and used for pull-down analysis: tggaaaaggcagctcactgaagcggctccct ggtaagtggagactgagcacttcagacac (fragment 1, nt 1493-1552, exon 3-intron 3, within this fragment, the potential hTra2-beta1-binding sites are underlined); ctgagatgcatttctggtc taaatctttgtagaaatgagtgcttgagcctgtttgtgtcg (fragment 2, nt 1557-1616, corresponding to the centre of intron 3); cctctga gaagtcttccctcttatatgtctctagtttttggaatggagcctcgcatccta (fragment 3, nt 1622-1681, intron 3-exon 4); accctttacaaggccagaaatg tattgttcaaacaacttcatggtcccagtgctcaaaga (fragment 4, nt 1686-1745, exon 4). As control, we also transcribed a sequence from a well-known binding site in exon 7 of the SMN2 gene (caaaaa gaaggaaggtgctcaca). In a second set of mutants, fragment 1 was deleted in the two potential hTRA2-beta1-binding sequences either singly or in tandem to yield mutant RNAs, mutation 1 (aaag deletion), mutation 2 (gaag deletion) and mutation 3 (both, aaag and gaag deletions).
Immunocytochemistry
Following experimental treatment, cell lines HeLa, Ishikawa, SK-OV-3 and MCF-7 were fixed using ROTI w Histofix formaldehyde fixation reagent (4% formaldehyde in PBS, pH 7, Carl Roth). Cyr61 and hTra2-beta1 protein expression were determined using polyclonal rabbit Cyr61 (H-78) antibody (Santa Cruz Biotechnology, Inc.) and rabbit IgG hTRA2-beta1 antibody [kindly provided by S. Stamm, (Stamm's Lab, Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, KY, USA) (28)].
For visualization of Cyr61 and hTRA2-beta1 expression, antigen retrieval and indirect immunoperoxidase technique were applied. Antigen retrieval was performed by heating the fixed cells on slides for 5 min in a 10 mmol/l sodium citrate buffer (pH 6.0). Inhibition of endogenous peroxidase was performed by 30 min incubation with 3% H 2 O 2 . Endogenous avidin-biotin was blocked by the use of a commercial biotin blocking system (DAKO, Dako GmbH) for 10 min. After two washes in trissaline buffer, slides were incubated with 1% goat serum for 30 min to block unspecific staining. The sections were exposed to Cyr61 antibody (1:500) or hTRA2-beta1 antibody (1:8000) overnight at room temperature (RT). Slides were incubated with biotinylated anti-rabbit immunoglobulins for 60 min at RT and treated with streptavidin-peroxidase (DAKO). Staining was achieved by 3,3-diaminobenzidine (Vectastain, Vector Laboratories, Inc., Linaris GmbH) and the slides were counterstained with hemalaun.
Equipment for documentation and evaluation
Documentation of electrophoresis gels was performed using DIANA II (CCD Camera System, Raytest Isotopenmessgeräte GmbH) and evaluation with AIDA (2D densitometry) software (Raytest). Microscopic examination of cells was performed using Axioplan 2 microscope (KARL ZEISS Microimaging GmbH) with 40 × Plan Neofluor objective lenses at RT (228C), and documentation with Canon Powershot G5 camera and Canon Zoom Browser software. Image processing and figure design with MS Office Visio 2003 and Adobe Photoshop CS2 Version 9.
